Drug Trial Radar · NCT05891483
Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
Sep 4, 2023
Primary completion
Jan 21, 2026
Study completion Jan 21, 2026
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
SHR-1905 InjectionDrug
SHR-1905 Injection
SHR-1905 Placebo InjectionDrug
SHR-1905 Placebo Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nasal polyp scores (NPS)Time frame: Baseline to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye & Ent Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.